Abstract:
The present invention refers to a process for producing 5‐[4‐(2‐hydroxy‐2‐methyl)‐1‐oxo‐prop‐1‐yl]‐3‐[4‐(2‐hydroxy‐2‐methyl)‐1‐oxo‐prop‐1‐yl‐ phenyl]‐2,3‐dihydro‐1,1,3‐trimethyl‐ H‐indene (dimer isomer 5) that comprises the synthesis from cumene and dimerization of 2‐methyl‐1‐(4‐(prop‐1‐en‐2‐yl)phenyl)propan‐1‐one in the presence of acid catalysts.
Abstract:
Die vorliegende Erfindung betrifft Verbindungen gemäß Formel (1) bzw. Formel (2), welche sich für die Verwendung in elektronischen Vorrichtungen, insbesondere organischen Elektrolumineszenzvorrichtungen, eignen, sowie elektronische Vorrichtungen, welche diese Verbindungen enthalten.
Abstract:
Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.
Abstract:
Disclosed are organic electroluminescent compounds and organic electroluminescent devices employing said compounds. The organic electroluminescent compounds of the invention are defined by chemical formula [1], Chemical Formula 1 The compounds, when used in an electron transport layer of an organic electroluminescent device, reduce power consumption and operation voltage of said device. Provided are novel organic electroluminescent compounds and an organic electroluminescent device using the same. Since the organic electroluminescent compound exhibits good luminous efficiency and excellent life property, it may be used to manufacture OLED devices having very superior operation life and consuming less power due to improved power efficiency.
Abstract:
Provided is an acenaphtho[1,2-k]benzo[e]acephenanthrene derivative represented by general formula (1): wherein R 1 to R 16 are each independently selected from a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group; and at least one of R 1 to R 8 and R 10 to R 15 is selected from a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heterocyclic group.
Abstract:
The invention relates to 1,3,5-benzene derivatives and corresponding radical-anions and radical-cations of the general formula (I): wherein: Z is a group chosen from among C=O, CONH, CONR, CONAr; m is an integer >0, preferably m = 1; A is a group chosen from among the radicals of: biphenylene, carbazole, fluoranthene, fluorene, dibenzothiofene, dibenzofurane, fluorenone, bifluorenylidene, triphenylene, cyclooctatetraene (COT), dibenzocyclooctatetraene (DBCOT), coronene, acenaphtylene, triptycene, azulene, benzo(ghi)fluoranthene, 2-phenyl-l,3,4-oxadiazole, anthracene. R and Ar are alkyl and aryl respectively and have the meaning indicated herein below. The invention also relates to the method for synthesizing said compounds and to their use in particular as components of matrices in the molecular electronics, spintronics and telecom fields.
Abstract:
Die vorliegende Erfindung betrifft die Verbindungen der Formel (1) bis (6) und organische Elektrolumineszenzvorrichtungen, insbesondere blau emittierende Vorrichtungen, in denen diese Verbindungen als Hostmaterial oder Dotand in der emittierenden Schicht und/oder als Lochtransportmaterial und/oder als Elektronentransportmaterial verwendet werden.
Abstract:
The present invention relates to a cyclisation process of forming a multiple ring compound from an isoprenoid compound. The cyclisation process involves reacting the isoprenoid compound with an acetal initiator under conditions sufficient to form the multiple ring compound. The isoprenoid compound is contacted with an initiator an optionally with a catalyst. Cyclisation occurs by reaction of the initiator with the isoprenoid compound. Cyclic aceta compounds wherein the acetal forms part of 6-membered unsaturated ring are also defined.
Abstract:
A process for preparing a compound of Formula (I); where Q completes an optionally substituted 5- or 6-member saturated carbocyclic ring and R is optionally substituted phenyl or optionally substituted C3-C6 cycloalkyl which process comprises the rearrangement of a compound of Formula (II); where Q and R are as defined in relation to Formula (I) in a polar aprotic, dipolar aprotic or aromatic hydrocarbon solvent in the presence of a moderate base and an azole.
Abstract:
The present invention relates to therapeutically active heterocyclic compounds of formula (I) wherein n is 0, 1 or 2; and X is -O-, -S, -N(R )- or -CH2-; and R is H, NH2, NHR or OH; and R and R independently are H, COOH, COOR , CONH2, CONHR , CON(R )2, CONHSO2R or tetrazole; and R is H, OH, NH2, NHR , CF3, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, C3-6-cycloalkyl, phenyl or C1-4-alkoxy; and R is H, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl, phenyl or C3-6-cycloalkyl; and ring A can be partly or completely saturated or aromatic, or a salt thereof with a pharmaceutically acceptable acid or base, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to the metabotropic glutamate receptor system.